RSS Feeds
Search

Out-licensing

Up-to-date access to technology licensing opportunities worldwide.

Licensing opportunities

Displaying 1..1 of 1 - per page
Order by
Optimised pulmonary and nasal therapies using supercritical fluid (SCF) particle engineering
Supercritical fluid crystal and particle engineering to form particles with strong aerodynamic performance and exceptional size uniformity for optimised pulmonary/nasal delivery More
Displaying 1..1 of 1 - per page
Order by

Related Reports

Market Research Reports provided by reports.iptechex.com
Amyotrophic Lateral Sclerosis Therapy Area Pipeline Report
Nov 2010 - 144 pages - $1,495
Amyotrophic Lateral Sclerosis (ALS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Sep 2011 - 80 pages - $3,500
The Avicena Group, Inc. - Product Pipeline Review - Q4 2010
Nov 2010 - 37 pages - $500
Amyotrophic Lateral Sclerosis - Pipeline Review, Q1 2011
Feb 2011 - 69 pages - $500
The Market Outlook for Neurodegenerative Diseases
Sep 2010 - 137 pages - $3,835
Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2011
Sep 2011 - 122 pages - $500
The Avicena Group, Inc. – Product Pipeline Review – H2 2011
Sep 2011 - 31 pages - $500
Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) - Pipeline Assessment and Market Forecasts to 2017
Nov 2010 - 35 pages - $2,000
Amyotrophic Lateral Sclerosis Global Clinical Trials Review, Q1, 2011
Feb 2011 - 69 pages - $1,000
The Avicena Group, Inc. (AVCEE) - Strategic SWOT Analysis Review
May 2011 - 15 pages - $125
More Related Market Research Reports >>>

Your selection

Therapeutic target
Central Nervous System del
Amyotrophic lateral sclerosis del
Development phase
Phase III/IV del

Browse By

Industry sector
Animal health
Biotechnology
Diagnostic
Drug delivery
Drug discovery
Medical device
Pharmaceutical
Research tools

Clients in focus...

Get the Flash Player to see this rotator.

© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us